Abstract
Botulinum neurotoxins (BoNTs) are the most toxic proteins currently known. Current treatments for botulinum poisoning are all protein based with a limited window of opportunity. Inhibition of the BoNT light chain protease (LC) has emerged as a new therapeutic strategy for the treatment of botulism as it may provide an effective post-exposure remedy. As such, a small library of 40 betulin derivatives was synthesized and screened against the light chain of BoNT serotype A (LC/A); five positive hits (IC(50) <100 μM) were uncovered. Detailed evaluation of inhibition mechanism of three most active compounds revealed a competitive model, with sub-micromolar K(i) value for the best inhibitor (7). Unfortunately, an in vitro cell-based assay did not show any protection of rat cerebellar neurons against BoNT/A intoxication by 7.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Botulinum Toxins / chemical synthesis
-
Botulinum Toxins / chemistry*
-
Botulinum Toxins / pharmacology
-
Botulinum Toxins, Type A / antagonists & inhibitors*
-
Botulinum Toxins, Type A / metabolism
-
Neurons / drug effects
-
Protease Inhibitors / chemical synthesis*
-
Protease Inhibitors / chemistry
-
Protease Inhibitors / pharmacology
-
Rats
-
Small Molecule Libraries / chemical synthesis
-
Small Molecule Libraries / chemistry
-
Small Molecule Libraries / pharmacology
-
Structure-Activity Relationship
-
Succinates / chemical synthesis*
-
Succinates / chemistry
-
Succinates / pharmacology
-
Triterpenes / chemical synthesis*
-
Triterpenes / chemistry
-
Triterpenes / pharmacology
Substances
-
Protease Inhibitors
-
Small Molecule Libraries
-
Succinates
-
Triterpenes
-
Botulinum Toxins
-
Botulinum Toxins, Type A